Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
GlobeNewswire
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose..